Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.

Authors:
Qi H; Rizopoulos D; Lesaffre E; van Rosmalen J.

Journal:
Pharm Stat

Publication Year: 2022

DOI:
10.1002/pst.2195

PMCID:
PMC9356117

PMID:
35128780

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pharm Stat

Abbreviation: Pharm Stat

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Statistics as Topic

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies.
Hatayama T; Yasui S. (2022) - Transparency Score: 2/6
Decision rules for identifying combination therapies in open-entry, randomized controlled platform …
Meyer EL; Mesenbrink P; Dunger-Baldauf C and 4 more (2022) - Transparency Score: 4/6
Pairwise joint modeling of clustered and high-dimensional outcomes with covariate missingness in pe…
Gachau S; Njagi EN; Molenberghs G and 4 more (2022) - Transparency Score: 3/6
Should the two-trial paradigm still be the gold standard in drug assessment?
Zhan SJ; Kunz CU; Stallard N. (2022) - Transparency Score: 4/6
Standard and reference-based conditional mean imputation.
Wolbers M; Noci A; Delmar P and 3 more (2022) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"Funding information National Institutes of Aging, Grant/Award Number: U01AG010483; University of California, San Diego, Alzheimer's Disease Cooperative Study"

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025